UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of enzyme inhibition, ISSN 8755-5093, 1985
Journal
Current enzyme inhibition, ISSN 1573-4080, 2005
Journal
2013, ISBN 111848813X, 572
eBook
Journal of enzyme inhibition and medicinal chemistry, ISSN 1475-6366, 2002
Journal
The New England journal of medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 993 - 1004
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiology. Vascular system | Heart | Biological and medical sciences | General aspects | Medical sciences | Heart failure, cardiogenic pulmonary edema, cardiac enlargement | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Aminobutyrates - adverse effects | Hospitalization - statistics & numerical data | Male | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Heart Failure - drug therapy | Stroke Volume | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Neprilysin - antagonists & inhibitors | Female | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Angiotensin Receptor Antagonists - adverse effects | Heart Failure - mortality | Heart failure | Enalapril | Patient outcomes | Angiotensin | Enalaprilat | Dosage and administration | Research | Drug therapy | Enzymes | Statistical analysis | Mortality | Angioedema | Hypotension | Cough | Studies | Hyperkalemia | Death | Neprilysin | Heart diseases | Index Medicus | Abridged Index Medicus | MORTALITY | SURVIVAL | RANDOMIZED-TRIAL | RECEPTOR | Klinisk medicin | NEUTRAL ENDOPEPTIDASE INHIBITION | NATRIURETIC-PEPTIDE | Medicine | Clinical Medicine | CONVERTING ENZYME-INHIBITION | MORBIDITY | EJECTION FRACTION | General & Internal | DOUBLE-BLIND
Journal Article
Nature reviews cardiology, ISSN 1759-5002, 03/2017, Volume 14, Issue 3, pp. 171 - 186
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Biphenyl Compounds - pharmacokinetics | Tetrazoles - pharmacology | Humans | Angiotensin Receptor Antagonists - pharmacology | Heart Failure - physiopathology | Stroke Volume - drug effects | Biological Availability | Aminobutyrates - pharmacology | Heart Failure - metabolism | Heart Failure - drug therapy | Aminobutyrates - pharmacokinetics | Animals | Neprilysin - antagonists & inhibitors | Blood Pressure - drug effects | Enzymes | Proteases | Dilatation | Blood vessels | Regulation | Genetic aspects | Health aspects | Index Medicus
Journal Article
Biotechnology advances, ISSN 0734-9750, 05/2010, Volume 28, Issue 3, pp. 407 - 425
Enzyme inhibition | Membrane reactors | Glucose removal | Hydrolysis kinetics | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Biotechnology | Biological and medical sciences | Methods. Procedures. Technologies | Bioreactors | Various methods and equipments | Enzyme Inhibitors - metabolism | Lignin - physiology | Membranes, Artificial | Bacterial Physiological Phenomena | Cellobiose - metabolism | Equipment Design | Hydrolysis | Cellulases - metabolism | Models, Biological | Bioreactors - microbiology | Computer Simulation | Glucose - metabolism | Computer-Aided Design | Enzyme Activation | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2010, Volume 55, Issue 21, pp. 2299 - 2307
angiotensin type 1 receptor | angiotensin | angiotensin-converting enzyme inhibitors | atrial fibrillation | renin-angiotensin system | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Severity of Illness Index | Prognosis | Risk Assessment | Atrial Fibrillation - drug therapy | Humans | Male | Treatment Outcome | Anti-Arrhythmia Agents - therapeutic use | Randomized Controlled Trials as Topic | Animals | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Atrial Fibrillation - mortality | Primary Prevention - methods | Survival Analysis | Electrocardiography | Female | Renin-Angiotensin System - drug effects | Atrial Fibrillation - diagnosis | Atrial Fibrillation - prevention & control | Hypertension | Studies | Confidence intervals | Heart failure | Disease prevention | Cardiac arrhythmia | Enzymes | Heart attacks | Mortality | Drug therapy | Potassium
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 04/2011, Volume 54, Issue 7, pp. 2196 - 2206
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Amino Acid Sequence | Cell Survival - drug effects | Metals, Heavy - metabolism | Zinc Fingers | Enzyme Inhibitors - metabolism | Humans | Enzyme Inhibitors - pharmacology | Gene Expression Regulation, Neoplastic | Metals, Heavy - pharmacology | Models, Molecular | Molecular Sequence Data | DNA - metabolism | Antineoplastic Agents - chemistry | Poly(ADP-ribose) Polymerase Inhibitors | Antineoplastic Agents - metabolism | Poly(ADP-ribose) Polymerases - metabolism | Enzyme Inhibitors - chemistry | Cell Line, Tumor | Inhibitory Concentration 50 | Antineoplastic Agents - pharmacology | Metals, Heavy - chemistry | Poly(ADP-ribose) Polymerases - chemistry | Index Medicus
Journal Article
European journal of clinical pharmacology, ISSN 0031-6970, 1/2008, Volume 64, Issue 1, pp. 31 - 41
CYP3A4 inhibition | Biomedicine | Ketoconazole | Pharmacology/Toxicology | Metabolic inhibition | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Pharmacology. Drug treatments | Medical sciences | Erlotinib Hydrochloride | Protein Kinase Inhibitors - pharmacokinetics | Area Under Curve | Humans | Microsomes, Liver - metabolism | Middle Aged | Enzyme Inhibitors - pharmacology | Quinazolines - pharmacokinetics | Male | Forecasting | Ketoconazole - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Drug Interactions | Cytochrome P-450 CYP3A - metabolism | Computer Simulation | Adolescent | Adult | Aged | Physiological aspects | Computer-generated environments | Erlotinib | Computer simulation | Cytochrome P-450 | Enzymes | Side effects | Inhibitor drugs | Pharmacology | Metabolism | Cancer | Index Medicus
Journal Article